We are proud to announce that the Basaluzzo site has successfully renewed its GMP (Good Manufacturing Practice) certification issued by AIFA, the Italian Medicines Agency. This renewed authorization is valid for 42 months, extending until mid-2028, and represents a key milestone in maintaining the highest standards of pharmaceutical manufacturing.
Successful Completion of AIFA Inspection
The certification follows a comprehensive AIFA inspection carried out between January 13–17, 2025. During this review, inspectors assessed the effectiveness of our quality management system, confirming our compliance with international pharmaceutical standards. The process involved the dedication and collaboration of many colleagues across the site, once again highlighting the strength of our team and our shared commitment to quality and regulatory excellence.
Why GMP Certification Matters
GMP compliance is essential for all pharmaceutical companies operating in Italy. Without it, manufacturers cannot market their products either in domestic or international markets. By securing this renewal, the Basaluzzo site ensures continuity in supplying high-quality medicines and strengthens its role within the ICE Pharma Group and the broader global healthcare market.
Commitment to Quality and Global Healthcare
Maintaining GMP certification not only confirms regulatory compliance but also reinforces our mission to deliver safe, effective, and reliable pharmaceutical products. With this renewal, the Basaluzzo site continues to make a critical contribution to advancing healthcare in Italy and worldwide.